Spots Global Cancer Trial Database for neoplasms, ovarian
Every month we try and update this database with for neoplasms, ovarian cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer | NCT02582931 | Cancer of Ovary Cancer of the O... Neoplasms, Ovar... Ovarian Cancer Ovary Cancer Ovary Neoplasms | MRI-guided SBRT EORTC QLQ-C30 Q... EORTC QLQ-OV28 ... | 18 Years - | Washington University School of Medicine | |
| Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women | NCT01227928 | Neoplasms, Ovar... | Pazopanib Placebo compara... | 18 Years - | GlaxoSmithKline | |
| A Study of PF-07260437 in Advanced or Metastatic Solid Tumors | NCT05067972 | Ovarian Neoplas... Endometrial Neo... Breast Neoplasm... | PF-07260437 B7-H4 IHC | 18 Years - | Pfizer | |
| Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer | NCT00659178 | Neoplasms, Ovar... | SB-485232 (inte... | 18 Years - | GlaxoSmithKline | |
| The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer | NCT03162562 | Cancer of Ovary Neoplasms, Ovar... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovary Cancer | Oregovomab Poly ICLC | 18 Years - 90 Years | CanariaBio Inc. | |
| Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women | NCT01227928 | Neoplasms, Ovar... | Pazopanib Placebo compara... | 18 Years - | GlaxoSmithKline | |
| A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors | NCT00722293 | Neoplasms, Brea... | Doxorubicin Pazopanib (GW78... Epirubicin | 18 Years - | GlaxoSmithKline | |
| Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer | NCT05059782 | Ovarian Cancer Neoplasm, Ovari... Ovarian Neoplas... Ovary Neoplasms Neoplasm, Ovary Neoplasms, Ovar... Ovary Neoplasm Neoplasms, Ovar... Ovary Cancer Cancer, Ovarian... Cancers, Ovary Ovary Cancers Cancer, Ovarian Cancers, Ovaria... Ovarian Cancers Cancer of Ovary Cancer of the O... | chemotherapy, t... IFRT, IMRT or S... | 18 Years - | Health Science Center of Xi'an Jiaotong University | |
| The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer | NCT03162562 | Cancer of Ovary Neoplasms, Ovar... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovary Cancer | Oregovomab Poly ICLC | 18 Years - 90 Years | CanariaBio Inc. | |
| Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines | NCT02432378 | Cancer of Ovary Cancer of the O... Neoplasms, Ovar... Ovarian Cancer Ovary Cancer Ovary Neoplasms | Cisplatin + cel... Cisplatin + CKM... | 18 Years - | Roswell Park Cancer Institute | |
| Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer | NCT00316173 | Ovarian Cancer Neoplasms, Ovar... | topotecan CARBOPLATIN | 18 Years - | GlaxoSmithKline | |
| A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT05613088 | Neoplasms, Ovar... | MORAb-202 Paclitaxel Pegylated Lipos... Topotecan | 18 Years - | Bristol-Myers Squibb | |
| A Study of PF-07260437 in Advanced or Metastatic Solid Tumors | NCT05067972 | Ovarian Neoplas... Endometrial Neo... Breast Neoplasm... | PF-07260437 B7-H4 IHC | 18 Years - | Pfizer | |
| A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors | NCT00722293 | Neoplasms, Brea... | Doxorubicin Pazopanib (GW78... Epirubicin | 18 Years - | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
